血浆前蛋白转化酶枯草溶菌素9（PCSK9）水平与动脉粥样硬化患者冠状动脉狭窄的严重程度相关。 - Suppr

Plasma PCSK9 levels are associated with the severity of coronary stenosis in patients with atherosclerosis.

作者信息

Li Sha, Guo Yuan-Lin, Xu Rui-Xia, Zhang Yan, Zhu Cheng-Gang, Sun Jing, Qing Ping, Wu Na-Qiong, Li Jian-Jun

机构信息

Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, BeiLiShi Road 167, Beijing 100037, China.

出版信息

Int J Cardiol. 2014 Jul 1;174(3):863-4. doi: 10.1016/j.ijcard.2014.04.224. Epub 2014 Apr 26.

DOI:10.1016/j.ijcard.2014.04.224

PMID:24801085

Abstract

摘要

相似文献

Plasma PCSK9 levels are associated with the severity of coronary stenosis in patients with atherosclerosis.

Int J Cardiol. 2014 Jul 1;174(3):863-4. doi: 10.1016/j.ijcard.2014.04.224. Epub 2014 Apr 26.

Proprotein convertase subtilisin-kexin type 9 as a biomarker for the severity of coronary artery disease.

Ann Med. 2015;47(5):386-93. doi: 10.3109/07853890.2015.1042908. Epub 2015 Jul 10.

Plasma proprotein convertase subtilisin kexin type 9 levels are related to markers of cholesterol synthesis in familial combined hyperlipidemia.

Nutr Metab Cardiovasc Dis. 2013 Nov;23(11):1115-21. doi: 10.1016/j.numecd.2012.11.008. Epub 2013 Jan 18.

Association of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) With Cardiovascular Risk in Primary Prevention.

Arterioscler Thromb Vasc Biol. 2015 Oct;35(10):2254-9. doi: 10.1161/ATVBAHA.115.306172. Epub 2015 Aug 20.

Comparison of effects of pitavastatin versus pravastatin on serum proprotein convertase subtilisin/kexin type 9 levels in statin-naive patients with coronary artery disease.

Am J Cardiol. 2013 May 15;111(10):1415-9. doi: 10.1016/j.amjcard.2013.01.289. Epub 2013 Feb 20.

ABO blood group in relation to plasma lipids and proprotein convertase subtilisin/kexin type 9.

Nutr Metab Cardiovasc Dis. 2015 Apr;25(4):411-7. doi: 10.1016/j.numecd.2014.10.015. Epub 2014 Nov 5.

Association of plasma PCSK9 levels with white blood cell count and its subsets in patients with stable coronary artery disease.

Atherosclerosis. 2014 Jun;234(2):441-5. doi: 10.1016/j.atherosclerosis.2014.04.001. Epub 2014 Apr 14.

Relation of resistin to proprotein convertase subtilisin-kexin type 9 levels in coronary artery disease patients with different nutritional status.

J Endocrinol Invest. 2015 Dec;38(12):1291-9. doi: 10.1007/s40618-015-0310-y. Epub 2015 May 24.

Proprotein Convertase Subtilisin/Kexin type 9, C-Reactive Protein, Coronary Severity, and Outcomes in Patients With Stable Coronary Artery Disease: A Prospective Observational Cohort Study.

Medicine (Baltimore). 2015 Dec;94(52):e2426. doi: 10.1097/MD.0000000000002426.

Circulating PCSK9 levels are positively correlated with NMR-assessed atherogenic dyslipidaemia in patients with high cardiovascular risk.

Clin Sci (Lond). 2015 Jun;128(12):877-82. doi: 10.1042/CS20140832.

引用本文的文献

Diverse Effects of Cilostazol on Proprotein Convertase Subtilisin/Kexin Type 9 between Obesity and Non-Obesity.

Int J Mol Sci. 2022 Aug 29;23(17):9768. doi: 10.3390/ijms23179768.

Pcsk9 is associated with severity of coronary artery lesions in male patients with premature myocardial infarction.

Lipids Health Dis. 2021 May 27;20(1):56. doi: 10.1186/s12944-021-01478-w.

Sex Differences Associated With Circulating PCSK9 in Patients Presenting With Acute Myocardial Infarction.

Sci Rep. 2019 Feb 28;9(1):3113. doi: 10.1038/s41598-018-35773-x.

Clinical and genetic characteristics of familial hypercholesterolemia patients with type 2 diabetes.

J Endocrinol Invest. 2019 May;42(5):591-598. doi: 10.1007/s40618-018-0959-0. Epub 2018 Oct 1.

Association between proprotein convertase subtilisin/kexin type 9 and late saphenous vein graft disease after coronary artery bypass grafting: a cross-sectional study.

BMJ Open. 2018 Jul 10;8(7):e021951. doi: 10.1136/bmjopen-2018-021951.

Association between plasma levels of PCSK9 and the presence of coronary artery disease in Japanese.

Heart Vessels. 2019 Jan;34(1):19-28. doi: 10.1007/s00380-018-1218-1. Epub 2018 Jul 5.

Effect of cilostazol on plasma levels of proprotein convertase subtilisin/kexin type 9.

Oncotarget. 2017 Nov 14;8(64):108042-108053. doi: 10.18632/oncotarget.22448. eCollection 2017 Dec 8.

Accelerated atherosclerosis development in C57Bl6 mice by overexpressing AAV-mediated PCSK9 and partial carotid ligation.

Lab Invest. 2017 Aug;97(8):935-945. doi: 10.1038/labinvest.2017.47. Epub 2017 May 15.

Correlation between serum levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) and atherogenic lipoproteins in patients with coronary artery disease.

Lipids Health Dis. 2016 Sep 22;15(1):165. doi: 10.1186/s12944-016-0339-8.

Plasma Levels of Proprotein Convertase Subtilisin/Kexin Type 9 Are Elevated in Patients With Peripheral Artery Disease and Associated With Metabolic Disorders and Dysfunction in Circulating Progenitor Cells.

J Am Heart Assoc. 2016 May 20;5(5):e003497. doi: 10.1161/JAHA.116.003497.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Plasma PCSK9 levels are associated with the severity of coronary stenosis in patients with atherosclerosis.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献